NIH R01 · 2024
Project Abstract Pulmonary hypertension (PH), which causes right ventricular failure (RVF), is a life-threatening disease with limited long-term treatment options and a 5-year survival rate of only 50% despite advances in medical therapy, which temporarily ameliorate it. Lung transplant is the only definitive treatment; however, PH patients can acutely deteriorate and become ineligible for transplant. It is difficult to predict and intervene prior to RVF due to the limited physiologic understanding about end-stage PH and also because patients with severe PH do not tolerate exercise testing that would otherwise better predict their prognosis. Mechanical cardiopulmonary support (MCS)…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.